Dr. Rosenbaum's clinical interests include uveitis and autoimmune disease. His research interests include uveitis, cytokines, leukocyte and endothelial interactions. He currently heads the Uveitis Clinic and is the director of Inflammatory Research at OHSU. Dr. Rosenbaum is the Division Chief of Arthritis and Rheumatic Diseases. He is the Edward E. Rosenbaum Professor of Inflammatory Diseases. Dr. Rosenbaum received his medical degree in 1975 from Yale Medical School in New Haven, CT. He completed his Medicine residency and Rheumatology fellowship at Stanford Medical Center in Stanford, CA.
The promoter is used to drive expression of EYFP (Venus) in dendritic cells.
"Mice carrying the MHC class II restricted rearranged T cell receptor transgene, Tg(DO11.10)10Dlo, react to ovalbumin (OVA) peptide antigen. Intraperitoneal administration of OVA to transgenic mice results in a rapid deletion of the immature CD4+ CD8+ TCRlo thymocytes with progression to mature thymocytes. Apoptosis of cortical thymocytes within 20 hours of treatment indicates that apoptosis in important in the development of antigen-induced tolerance. Use of this rearranged T cell receptor transgene requires H2d background."
Foxp3-GFP-DTR (human diphtheria toxin receptor) C57BL/6 mice allow elimination of Foxp3+ Treg by treatment with Dx (diphtheria toxin).